Canaccord Adams maintains a 'Hold' rating on Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), but lowers price target to $11

Canaccord ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE